v3.25.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Operating activities    
Net earnings $ 10,046 $ 3,200
Noncash items:    
Depreciation and amortization 2,145 2,017
Deferred income taxes (87) (358)
Share-based compensation 572 594
Loss on sale of subsidiary and subsidiaries held for sale 56 8,311
Other, net 127 459
Net change in other operating items, net of effects from acquisitions and dispositions:    
Accounts receivable (1,681) (2,471)
Other assets (2,143) (4,121)
Medical costs payable 4,371 777
Accounts payable and other liabilities (480) 36
Unearned revenues (282) (554)
Cash flows from operating activities 12,644 7,890
Investing activities    
Purchases of investments (8,180) (10,130)
Sales of investments 5,181 5,288
Maturities of investments 4,326 4,621
Cash paid for acquisitions and other transactions, net of cash assumed (734) (3,031)
Purchases of property, equipment and capitalized software (1,784) (1,596)
Loans to care providers - cyberattack 0 (8,100)
Repayments of care provider loans - cyberattack 1,293 604
Other, net (1,618) (1,413)
Cash flows used for investing activities (1,516) (13,757)
Financing activities    
Common share repurchases (5,545) (3,072)
Cash dividends paid (3,912) (3,664)
Proceeds from common stock issuances 581 744
Repayments of long-term debt 0 (1,750)
(Repayments of) proceeds from short-term borrowings, net (1,403) 8,615
Proceeds from issuance of long-term debt 2,969 5,925
Customer funds administered (25) 990
Other, net (513) (753)
Cash flows (used for) from financing activities (7,848) 7,035
Effect of exchange rate changes on cash and cash equivalents 29 (44)
Increase in cash and cash equivalents, including cash within businesses held for sale 3,309 1,124
Less: net increase in cash within businesses held for sale (25) (265)
Net increase in cash and cash equivalents 3,284 859
Cash and cash equivalents, beginning of period 25,312 25,427
Cash and cash equivalents, end of period $ 28,596 $ 26,286